J. Flaherty

SWIFT: Prospective 48-Week Study to Evaluate Efficacy and Safety of Switching to Emtricitabine/Tenofovir From Lamivudine/Abacavir in Virologically Suppressed HIV-1 Infected Patients on a Boosted Protease Inhibitor Containing Antiretroviral Regimen

U. Bredeek, E. Dejesus, H. Khanlou, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

(S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): results of a phase I/II study of a novel antiviral nucleotide analogue.

J. C. Martin, J. Hannigan, J. Lalezari, 1995, The Journal of infectious diseases.

Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients

M. Polis, M. Wachsman, J. Lalezari, 1995, Antimicrobial agents and chemotherapy.

Patient-reported outcomes after simplification to a single tablet regimen of efavirenz (EFV)/emtricitabine (FTC)/tenofovir DF (TDF)

K. Mounzer, R. Ebrahimi, E. Dejesus, 2008 .

Simplification of therapy (ART) with efavirenz/emtricitabine/tenofovir DF single tablet regimen vs. continued ART in suppressed, HIV-infected patients

R. Ebrahimi, E. Dejesus, B. Young, 2008 .